文献速递脊柱关节炎

活动性银屑病关节炎患者不论基线人口学与疾病特征如何均可维持并改善古塞奇尤单抗应答:两项III期随机安慰剂对照研究至第52周的汇总结果

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
PubMed 文献 · RMD Open · 2022-01-01

汇总DISCOVER-1(N=381)和DISCOVER-2(N=739)两项III期随机安慰剂对照研究,评估古塞奇尤单抗100 mg Q4W或Q8W在活动性银屑病关节炎患者中的疗效。第24周古塞奇尤单抗Q4W组62%(232/373)、Q8W组60%(225/375)达到ACR20,安慰剂组为29%(109/372);各基线特征亚组中第52周应答率维持或升高。

要点

  • 第24周ACR20应答率:古塞奇尤单抗Q4W组62%(232/373)、Q8W组60%(225/375),安慰剂组29%(109/372)。
  • 古塞奇尤单抗第24周疗效在各患者亚组中均可观察到。
  • 各亚组内至第52周所有疾病领域应答率在两种方案下均维持或升高。

核心结论

  • 古塞奇尤单抗Q4W和Q8W在不同基线特征定义的各亚组中均使银屑病关节炎体征和症状获得稳健且持续的改善。

研究设计与样本

  • 汇总DISCOVER-1(N=381)和DISCOVER-2(N=739)两项III期随机安慰剂对照研究。
  • DISCOVER-1入组标准为≥3个肿胀关节和≥3个压痛关节且C反应蛋白(CRP)≥0.3 mg/dL;DISCOVER-2入组标准为≥5个肿胀关节和≥5个压痛关节、CRP≥0.6 mg/dL且生物制剂初治。
  • 随机患者接受100 mg古塞奇尤单抗于第0、4周给药后每4周或每8周一次(Q4W/Q8W),或接受安慰剂。

主要发现

  • 第24周古塞奇尤单抗Q4W组62%(232/373)和Q8W组60%(225/375)达到主要终点ACR20应答,安慰剂组为29%(109/372)。
  • 古塞奇尤单抗第24周的治疗效应在各患者亚组中均可观察到。
  • 在各患者亚组内,两种古塞奇尤单抗方案至第52周时所有疾病领域的应答率均维持或升高。

关键数值与推荐

  • 按性别、体重指数、银屑病关节炎病程、肿胀/压痛关节计数、CRP水平、银屑病体表面积百分比、银屑病面积和严重程度指数评分及基线传统合成改善病情抗风湿药使用情况评估关节(ACR20/50/70)、皮肤(IGA 0/1、IGA 0)、患者报告结局(健康评估问卷残疾指数/慢性病治疗功能评估-疲劳)和疾病严重程度(最小疾病活动度/银屑病关节炎疾病活动度评分低疾病活动度)终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics. METHODS: Adults with active PsA despite standard therapies were enrolled in DISCOVER-1 (≥3 swollen and ≥3 tender joints, C reactive protein (CRP) level ≥0.3 mg/dL) and DISCOVER-2 (≥5 swollen and ≥5 tender joints, CRP ≥0.6 mg/dL, biological-naïve). Randomised patients received 100 mg guselkumab at weeks 0, 4, and then every 4 or 8 weeks (Q4W/Q8W) or placebo. Guselkumab effects on joint (ACR20/50/70), skin (IGA 0/1, IGA 0), patient-reported outcome (Health Assessment Questionnaire Disability Index/Functional Assessment of Chronic Illness Therapy-Fatigue) and disease severity (minimal disease activity/PsA Disease Activity Score low disease activity) endpoints were evaluated by patient sex, body mass index, PsA duration, swollen/tender joint counts, CRP level, percent body surface area with psoriasis, Psoriasis Area and Severity Index score, and conventional synthetic disease-modifying antirheumatic drug use at baseline. RESULTS: Baseline patients characteristics in DISCOVER-1 (N=381) and DISCOVER-2 (N=739) were well balanced across randomised groups. At week 24, 62% (232/373) and 60% (225/375), respectively, of guselkumab Q4W-treated and Q8W-treated patients pooled across DISCOVER-1 and DISCOVER-2 achieved the primary endpoint of ACR20 response versus 29% (109/372) of placebo-treated patients. Guselkumab treatment effect at week 24 was observed across patient subgroups. Within each patient subgroup, response rates across all disease domains were sustained or increased at week 52 with both guselkumab regimens. CONCLUSIONS: Guselkumab Q4W and Q8W resulted in robust and sustained improvements in PsA signs and symptoms consistently in subgroups of patients defined by diverse baseline characteristics. TRIAL REGISTRATION NUMBERS: NCT03162796, NCT03158285.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ritchlin CT, Mease PJ, Boehncke WH, et al. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 2022. PMID: 35296534. doi:10.1136/rmdopen-2022-002195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。